ST香雪：目前整体经营情况正常 创新药研发取得新突破

Core Viewpoint - ST Xiangxue expects a net profit loss of 635 million to 934 million yuan for the year 2025, primarily due to intensified market competition, liquidity crisis, high financial costs, and asset impairment [1] Group 1: Financial Performance - The company anticipates a significant loss in net profit for 2025, ranging from 635 million to 934 million yuan [1] - Factors affecting performance include increased market competition, liquidity issues, high financial expenses, and asset impairment [1] Group 2: Business Operations - Despite short-term operational challenges, the overall business situation remains normal, and the company aims to enhance profitability for sustainable operations [1] - The company has made significant progress in innovative drug research and development [1] Group 3: R&D Achievements - The company's subsidiary, Xiangxue Life Science Technology, has received clinical approval for the TCR-T cell therapy product "XLS-103 Injection" for treating advanced non-small cell lung cancer and advanced pancreatic cancer with specific genetic mutations [1] - This approval marks the sixth and seventh clinical trial permits obtained by Xiangxue Life Science based on its core TCR-T cell therapy technology and R&D platform [1] - The company has established a comprehensive platform covering antigen peptide discovery, TCR affinity optimization, and full-process development, with three TCR-T products targeting various solid tumors [1]